Review



pgl3-u6-luc  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Addgene inc pgl3-u6-luc
    VHSV M blocks nascent cellular RNA synthesis. (A) EPC cells were left untreated, treated with 2 μg/ml α-amanitin or 1 μg/ml actinomycin D, or infected with VHSV-IVb (MOI = 1) for 24 h and then cultured in 100 μM 5-EU for 2 h. 5-EU was visualized with Alexa Fluor 594 via a click chemistry reaction. VHSV-transfected cells were visualized using a polyclonal anti-VHSV antibody, followed by goat anti-rabbit FITC secondary staining. (B) EPC cells were cotransfected with 0.4 μg GFP and 0.1 μg IVb M for 24 h and then labeled with 100 μM 5-EU for 2 h. 5-EU was visualized with Alexa Fluor 594 via a click chemistry reaction. (C) EPC cells were transfected with an SV40/luc, ITS1/luc, or <t>U6/luc</t> reporter construct with 0.25 μg of pCD-M per 1 × 106 cells for 24 h, followed by total RNA extraction and reverse transcription to cDNA. Luciferase mRNA levels were quantified by RT-qPCR and normalized to EPC β-actin mRNA levels. (D) The data in panel C are expressed as a percentage of the control values for each construct, demonstrating that relative levels of inhibition were similar for all.
    Pgl3 U6 Luc, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pgl3-u6-luc/product/Addgene inc
    Average 90 stars, based on 1 article reviews
    pgl3-u6-luc - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Role of Viral Hemorrhagic Septicemia Virus Matrix (M) Protein in Suppressing Host Transcription"

    Article Title: Role of Viral Hemorrhagic Septicemia Virus Matrix (M) Protein in Suppressing Host Transcription

    Journal: Journal of Virology

    doi: 10.1128/JVI.00279-17

    VHSV M blocks nascent cellular RNA synthesis. (A) EPC cells were left untreated, treated with 2 μg/ml α-amanitin or 1 μg/ml actinomycin D, or infected with VHSV-IVb (MOI = 1) for 24 h and then cultured in 100 μM 5-EU for 2 h. 5-EU was visualized with Alexa Fluor 594 via a click chemistry reaction. VHSV-transfected cells were visualized using a polyclonal anti-VHSV antibody, followed by goat anti-rabbit FITC secondary staining. (B) EPC cells were cotransfected with 0.4 μg GFP and 0.1 μg IVb M for 24 h and then labeled with 100 μM 5-EU for 2 h. 5-EU was visualized with Alexa Fluor 594 via a click chemistry reaction. (C) EPC cells were transfected with an SV40/luc, ITS1/luc, or U6/luc reporter construct with 0.25 μg of pCD-M per 1 × 106 cells for 24 h, followed by total RNA extraction and reverse transcription to cDNA. Luciferase mRNA levels were quantified by RT-qPCR and normalized to EPC β-actin mRNA levels. (D) The data in panel C are expressed as a percentage of the control values for each construct, demonstrating that relative levels of inhibition were similar for all.
    Figure Legend Snippet: VHSV M blocks nascent cellular RNA synthesis. (A) EPC cells were left untreated, treated with 2 μg/ml α-amanitin or 1 μg/ml actinomycin D, or infected with VHSV-IVb (MOI = 1) for 24 h and then cultured in 100 μM 5-EU for 2 h. 5-EU was visualized with Alexa Fluor 594 via a click chemistry reaction. VHSV-transfected cells were visualized using a polyclonal anti-VHSV antibody, followed by goat anti-rabbit FITC secondary staining. (B) EPC cells were cotransfected with 0.4 μg GFP and 0.1 μg IVb M for 24 h and then labeled with 100 μM 5-EU for 2 h. 5-EU was visualized with Alexa Fluor 594 via a click chemistry reaction. (C) EPC cells were transfected with an SV40/luc, ITS1/luc, or U6/luc reporter construct with 0.25 μg of pCD-M per 1 × 106 cells for 24 h, followed by total RNA extraction and reverse transcription to cDNA. Luciferase mRNA levels were quantified by RT-qPCR and normalized to EPC β-actin mRNA levels. (D) The data in panel C are expressed as a percentage of the control values for each construct, demonstrating that relative levels of inhibition were similar for all.

    Techniques Used: Infection, Cell Culture, Transfection, Staining, Labeling, Construct, RNA Extraction, Reverse Transcription, Luciferase, Quantitative RT-PCR, Control, Inhibition

    Primers for PCR analysis and cloning
    Figure Legend Snippet: Primers for PCR analysis and cloning

    Techniques Used: Sequencing, Virus



    Similar Products

    pgl3-u6-luc  (Promega)
    90
    Promega pgl3-u6-luc
    Pgl3 U6 Luc, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pgl3-u6-luc/product/Promega
    Average 90 stars, based on 1 article reviews
    pgl3-u6-luc - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    pgl3-u6-luc  (Addgene inc)
    90
    Addgene inc pgl3-u6-luc
    VHSV M blocks nascent cellular RNA synthesis. (A) EPC cells were left untreated, treated with 2 μg/ml α-amanitin or 1 μg/ml actinomycin D, or infected with VHSV-IVb (MOI = 1) for 24 h and then cultured in 100 μM 5-EU for 2 h. 5-EU was visualized with Alexa Fluor 594 via a click chemistry reaction. VHSV-transfected cells were visualized using a polyclonal anti-VHSV antibody, followed by goat anti-rabbit FITC secondary staining. (B) EPC cells were cotransfected with 0.4 μg GFP and 0.1 μg IVb M for 24 h and then labeled with 100 μM 5-EU for 2 h. 5-EU was visualized with Alexa Fluor 594 via a click chemistry reaction. (C) EPC cells were transfected with an SV40/luc, ITS1/luc, or <t>U6/luc</t> reporter construct with 0.25 μg of pCD-M per 1 × 106 cells for 24 h, followed by total RNA extraction and reverse transcription to cDNA. Luciferase mRNA levels were quantified by RT-qPCR and normalized to EPC β-actin mRNA levels. (D) The data in panel C are expressed as a percentage of the control values for each construct, demonstrating that relative levels of inhibition were similar for all.
    Pgl3 U6 Luc, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pgl3-u6-luc/product/Addgene inc
    Average 90 stars, based on 1 article reviews
    pgl3-u6-luc - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    VHSV M blocks nascent cellular RNA synthesis. (A) EPC cells were left untreated, treated with 2 μg/ml α-amanitin or 1 μg/ml actinomycin D, or infected with VHSV-IVb (MOI = 1) for 24 h and then cultured in 100 μM 5-EU for 2 h. 5-EU was visualized with Alexa Fluor 594 via a click chemistry reaction. VHSV-transfected cells were visualized using a polyclonal anti-VHSV antibody, followed by goat anti-rabbit FITC secondary staining. (B) EPC cells were cotransfected with 0.4 μg GFP and 0.1 μg IVb M for 24 h and then labeled with 100 μM 5-EU for 2 h. 5-EU was visualized with Alexa Fluor 594 via a click chemistry reaction. (C) EPC cells were transfected with an SV40/luc, ITS1/luc, or U6/luc reporter construct with 0.25 μg of pCD-M per 1 × 106 cells for 24 h, followed by total RNA extraction and reverse transcription to cDNA. Luciferase mRNA levels were quantified by RT-qPCR and normalized to EPC β-actin mRNA levels. (D) The data in panel C are expressed as a percentage of the control values for each construct, demonstrating that relative levels of inhibition were similar for all.

    Journal: Journal of Virology

    Article Title: Role of Viral Hemorrhagic Septicemia Virus Matrix (M) Protein in Suppressing Host Transcription

    doi: 10.1128/JVI.00279-17

    Figure Lengend Snippet: VHSV M blocks nascent cellular RNA synthesis. (A) EPC cells were left untreated, treated with 2 μg/ml α-amanitin or 1 μg/ml actinomycin D, or infected with VHSV-IVb (MOI = 1) for 24 h and then cultured in 100 μM 5-EU for 2 h. 5-EU was visualized with Alexa Fluor 594 via a click chemistry reaction. VHSV-transfected cells were visualized using a polyclonal anti-VHSV antibody, followed by goat anti-rabbit FITC secondary staining. (B) EPC cells were cotransfected with 0.4 μg GFP and 0.1 μg IVb M for 24 h and then labeled with 100 μM 5-EU for 2 h. 5-EU was visualized with Alexa Fluor 594 via a click chemistry reaction. (C) EPC cells were transfected with an SV40/luc, ITS1/luc, or U6/luc reporter construct with 0.25 μg of pCD-M per 1 × 106 cells for 24 h, followed by total RNA extraction and reverse transcription to cDNA. Luciferase mRNA levels were quantified by RT-qPCR and normalized to EPC β-actin mRNA levels. (D) The data in panel C are expressed as a percentage of the control values for each construct, demonstrating that relative levels of inhibition were similar for all.

    Article Snippet: Primers for PCR analysis and cloning Luciferase driven by a human U6 promoter reporter construct (pGL3-U6-Luc) was generated by subcloning the human U6 promoter from the pLKO.1 puro vector (Addgene plasmid 10879) into the pGL3 luciferase reporter vector (Promega E1751) upstream of the luciferase gene using Gibson Assembly (NEB E5520).

    Techniques: Infection, Cell Culture, Transfection, Staining, Labeling, Construct, RNA Extraction, Reverse Transcription, Luciferase, Quantitative RT-PCR, Control, Inhibition

    Primers for PCR analysis and cloning

    Journal: Journal of Virology

    Article Title: Role of Viral Hemorrhagic Septicemia Virus Matrix (M) Protein in Suppressing Host Transcription

    doi: 10.1128/JVI.00279-17

    Figure Lengend Snippet: Primers for PCR analysis and cloning

    Article Snippet: Primers for PCR analysis and cloning Luciferase driven by a human U6 promoter reporter construct (pGL3-U6-Luc) was generated by subcloning the human U6 promoter from the pLKO.1 puro vector (Addgene plasmid 10879) into the pGL3 luciferase reporter vector (Promega E1751) upstream of the luciferase gene using Gibson Assembly (NEB E5520).

    Techniques: Sequencing, Virus